XML 44 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
Non-controlling Interest
9 Months Ended
Sep. 30, 2015
Noncontrolling Interest [Abstract]  
Noncontrolling Interest Disclosure [Text Block]
9.
Non-controlling Interest
 
On August 29, 2015, the Company, Biomics and Mark Pimentel, M.D. entered into an amendment to the Stock Purchase Agreement they entered into dated December 3, 2013, which accelerated the date upon which Dr. Pimentel could exchange his shares of common stock in Biomics for shares of the Company’s common stock. On August 29, 2015, Dr. Pimentel notified the Company of his intent to exchange all of the shares of common stock in Biomics, 8.5%, owned by him for 1,350,000 shares of the Company’s common stock in accordance with the terms of the Stock Purchase Agreement, as amended. On August 31, 2015, the Company issued 1,350,000 shares of the Company’s common stock to Dr. Pimentel in exchange for all of the shares of common stock of Biomics held by Dr. Pimentel.
 
The Company’s non-controlling interest is accounted for under ASC 810, Consolidation (“ASC 810”) and represents the minority shareholder’s ownership interest related to the Company’s subsidiary, Biomics. In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common shareholders on the face of the consolidated Statements of Operations. After Dr. Pimentel’s transaction, the Company’s equity interest in Biomics is 88.5% and the non-controlling stockholder’s interest is 11.5%. As of September 30, 2015, the accumulated net loss attributable to the non-controlling interest is $733,000  that includes $984,000 of prior period losses attributable to minority stockholders, the reversal of Dr. Pimentel’s losses of $505,000 associated with the exchange of his shares of common stock in Biomics for shares of the Company’s common stock, and current period losses of $254,000 attributable to minority stockholders. Management considers the amounts which should have been recorded in prior periods to be immaterial.